Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974165 | 0.91 | NPC1 (0.53) | MAPTNPC1RAB9ATDP1KMT2A | |
| SCHEMBL27617094 | 0.89 | RAB9A (0.56) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL28596462 | 0.83 | ALDH1A1 (0.57) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1772578 | 0.83 | MAPT (0.54) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL7035834 | 0.83 | ACHE (0.57) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL7035833 | 0.83 | NPC1 (0.46) | MAPTNPC1RAB9ATDP1KMT2A | |
| SCHEMBL22164075 | 0.83 | ELANE (0.48) | MAPTNPC1RAB9AALDH1A1GAA | |
| SCHEMBL8702382 | 0.83 | MEN1 (0.56) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL71038 | 0.82 | LMNA (0.54) | MAPTNPC1RAB9ATDP1KMT2A | |
| SCHEMBL3156019 | 0.81 | MAPT (0.52) | MAPTRAB9ATDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573887-B2 | Naphthalene derivative | DAITO CHEMIX CORPORATION (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-2852590-B1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| EP-2852590-B1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| CN-104395309-B | Cyclic bridgehead ether DGAT1 inhibitors | 诺华股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| EP-2599771-B1 | NAPHTHALENE DERIVATIVE | DAITO CHEMIX CORP (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-9206129-B2 | Agent for treatment of eye diseases | DAITO CHEMIX CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2623494-B1 | AGENT FOR TREATMENT OF EYE DISEASES | DAITO CHEMIX CORP (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-20150166563-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150166563-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| EP-2852590-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | Novartis AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-8993619-B2 | Cyclic bridgehead ether DGAT1 inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8993619-B2 | Cyclic bridgehead ether DGAT1 inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| CN-104395309-A | Cyclic bridgehead ether dgat1 inhibitors | NOVARTIS AG | 2015-03-04 | — | — | CN | disclosed |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | KYOTO UNIVERSITY (JP) | 2014-05-29 | — | — | US | disclosed |
| US-20130289058-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-10-31 | — | — | US | disclosed |
| WO-2013160873-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2013-10-31 | — | — | WO | disclosed |
| EP-2623494-A1 | AGENT FOR TREATMENT OF EYE DISEASES | Daito Chemix Corporation (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130184241-A1 | Naphthalene Derivative | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2599771-A1 | NAPHTHALENE DERIVATIVE | Daito Chemix Corporation (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2005037839-A1 | NORCANTHARIDIN DERIVATIVE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | ENTOMED (FR) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | PDE6A, ALDH1A2, PDE6D | MAPT 513/4885NPC1 148/4885RAB9A 208/4885 |
| US-20130184241-A1 | Naphthalene Derivative | VCP, NOC2L, VAT1 | MAPT 121/4885NPC1 5/4885RAB9A 1989/4885 |
| US-20150166563-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | DGAT1, DGAT2, ACAT1 | MAPT 2704/4885NPC1 113/4885RAB9A 1970/4885 |
| US-20130289058-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | DGAT1, DGAT2, ACAT1 | MAPT 2704/4885NPC1 113/4885RAB9A 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.